Initial Treatment for Mast Cell Activation Syndrome Causing Enteritis

First-Line Medication Approach

The initial treatment for mast cell activation syndrome (MCAS) causing enteritis should include a combination of H1 and H2 receptor antihistamines, with the addition of oral cromolyn sodium as a mast cell stabilizer specifically targeting gastrointestinal symptoms 1, 2
Begin with H1 receptor antihistamines, particularly second-generation non-sedating options such as cetirizine or fexofenadine, which can be used at 2-4 times FDA-approved doses to effectively reduce inflammation and gastrointestinal symptoms 1, 2
Add an H2 receptor antagonist (famotidine, ranitidine, or cimetidine) to specifically target abdominal symptoms and complement the H1 blocker effects 2, 3

Consider cyproheptadine, which functions as both a sedating H1 blocker and serotonin receptor antagonist, making it particularly effective for treating diarrhea and nausea in MCAS 1, 2

Add a cysteinyl leukotriene inhibitor (montelukast) or 5-lipoxygenase inhibitor (zileuton) if gastrointestinal symptoms persist, as these agents can specifically reduce gastrointestinal manifestations, particularly if urinary LTE4 levels are elevated 1, 3
Consider a short course of oral corticosteroids (prednisone 0.5 mg/kg/day with slow taper over 1-3 months) for refractory enteritis symptoms that don't respond to first-line therapy 1, 2

Ensure patients have emergency medications available, including epinephrine autoinjector for those with history of systemic reactions 1, 5
Monitor response to therapy by tracking symptom improvement; treatment efficacy may take weeks to become apparent, particularly with cromolyn sodium 3

First-generation H1 antihistamines (diphenhydramine, hydroxyzine) can cause significant sedation and cognitive decline, particularly in elderly patients, and should be used with caution 2, 3
Opioids should be used cautiously for pain management in MCAS patients, with fentanyl and remifentanil being safer options than morphine or codeine 6, 5